Can-Fite BioPharma (CANF) Institutional Ownership $0.69 -0.01 (-1.14%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$0.69 0.00 (-0.01%) As of 08/8/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Can-Fite BioPharma (NYSE:CANF)CurrentInstitutional OwnershipPercentage21.00%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$441.80KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$16.53K Get CANF Insider Trade Alerts Want to know when executives and insiders are buying or selling Can-Fite BioPharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CANF Institutional Buying and Selling by Quarter Can-Fite BioPharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/29/2025Rhumbline Advisers38,268$57K0.0%+42.4%1.081% 4/8/2025Rhumbline Advisers38,268$57K0.0%+42.4%1.081% 2/17/2025BNP Paribas Financial Markets25,185$41K0.0%N/A0.711% 2/14/2025Two Sigma Securities LLC19,395$32K0.0%-34.4%0.548% 1/30/2025Rhumbline Advisers26,880$44K0.0%+58.6%0.759% 8/15/2024Armistice Capital LLC518,853$1.34M0.0%+35.5%14.657% 2/13/2024Armistice Capital LLC154,363$340K0.0%N/A4.361% 1/17/2024Schechter Investment Advisors LLC20,077$44K0.0%N/A0.567% 2/10/2022 Acadian Asset Management LLC28,601$36K0.0%-75.1%0.105% 11/16/2021Cetera Advisor Networks LLC130,776$217K0.0%-16.9%0.607% 10/15/2021 Fifth Third Bancorp30,000$50K0.0%N/A0.149% 8/6/2021StoneX Group Inc.40,000$91K0.0%N/A0.233% 5/21/2021Citadel Advisors LLC60,077$148K0.0%N/A0.349% (Data available from 1/1/2016 forward) CANF Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CANF shares? During the previous two years, the following institutional investors and hedge funds held shares of Can-Fite BioPharma shares: Armistice Capital LLC ($1.34M), Rhumbline Advisers ($57K), Schechter Investment Advisors LLC ($44K), and BNP Paribas Financial Markets ($41K), Two Sigma Securities LLC ($32K).Learn more on Can-Fite BioPharma's institutional investors. What percentage of Can-Fite BioPharma's stock is owned by institutional investors? 21.00% of Can-Fite BioPharma's stock is owned by institutional investors. Learn more on CANF's institutional investor holdings. Which institutional investors have been buying Can-Fite BioPharma's stock? The following institutional investors have purchased Can-Fite BioPharma's stock in the last 24 months: Armistice Capital LLC ($290.42K), Rhumbline Advisers ($32.71K), BNP Paribas Financial Markets ($25.19K), and Schechter Investment Advisors LLC ($20.08K). How much institutional buying is happening at Can-Fite BioPharma? Institutional investors have bought a total of 193,951 shares in the last 24 months. This purchase volume represents approximately $441.80K in transactions. Which of Can-Fite BioPharma's major shareholders have been selling company stock? The following institutional investors have sold Can-Fite BioPharma stock in the last 24 months: Two Sigma Securities LLC ($10.18K). How much institutional selling is happening at Can-Fite BioPharma? Institutional investors have sold a total of 10,175 shares in the last 24 months. This volume of shares sold represents approximately $16.53K in transactions. Related Companies Acurx Pharmaceuticals Major Shareholders Dogwood Therapeutics Major Shareholders X4 Pharmaceuticals Major Shareholders Aprea Therapeutics Major Shareholders Soligenix Major Shareholders Sonnet BioTherapeutics Major Shareholders Addex Therapeutics Major Shareholders Cellectar Biosciences Major Shareholders Cyclerion Therapeutics Major Shareholders Synaptogenix Major Shareholders This page (NYSE:CANF) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.